Here is a good news for both diabetes and kidney patients. A popular anti-diabetes drug rosiglitazone is found effective in kidney diseases too. The study published in Clinical Journal of the American Society Nephrology, reports the phase 1 clinical findings indicate that the drug warrants further study in phase 2 and phase 3 trials.
To investigate the potential of rosiglitazone for treating patients with FSGS, Howard Trachtman, MD, at the Schneider Children’s Hospital in New Hyde Park, New York, and his colleagues designed a phase 1 clinical trial in patients with this condition. The study is being done in conjunction with Debbie Gipson, MD, MSPH, at the University of North Carolina in Chapel Hill, North Carolina. It is part of a comprehensive strategy to develop anti-fibrotic therapies for FSGS.
The investigators studied 11 patients with FSGS whose condition had not responded to previous treatment with steroids and other immunosuppressive drugs.Patients receiving rosiglitazone at a dose of three mg/m2 per day for 16 weeks experienced no serious adverse effects, including no cardiovascular complications that have been associated with rosiglitazone in other studies.
According to the authors, the results from this study indicate that rosiglitazone warrants further investigation for the treatment of FSGS.
Source: Renal Business Today